ClinicalTrials.gov
ClinicalTrials.gov Menu

Identifying Methylation Biomarkers for Monitoring Bladder Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00244205
Recruitment Status : Unknown
Verified November 2005 by Copenhagen University Hospital at Herlev.
Recruitment status was:  Recruiting
First Posted : October 26, 2005
Last Update Posted : November 15, 2005
Sponsor:
Information provided by:
Copenhagen University Hospital at Herlev

Brief Summary:
To investigate the methylation status of 4-6 genes in Urine and matching bladder tissue biopsies, in order to find methylation markers for use in a noninvasive test in monitoring patients with bladder tumors.

Condition or disease Intervention/treatment
Bladder Cancer Procedure: Identifying genes methylated in urine

Study Type : Observational
Enrollment : 120 participants
Observational Model: Case Control
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Using PCR Technology (Polymerase Chain Reaction Technology) for Monitoring Patients With Bladder Tumors - Optimizing Genanalyses for Clinical Use.
Study Start Date : November 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Bladder Cancer





Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients with bladder tumors and patients with benign urinary tract conditions with no clinical suspicion of bladder cancer.

Exclusion Criteria:

  • Patients with competing urinary and systemic diseases, pregnant and patients under 18 years of age.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00244205


Contacts
Contact: Reza R Serizawa, MD +45 44884787 ext 82607 rerase01@herlevhosp.kbhamt.dk
Contact: Jørgen H Andersen johvan01@herlevhosp.kbhamt.dk

Locations
Denmark
Copenhagen University Hospital at Herlev Recruiting
Herlev, Copenhagen, Denmark, 2730
Contact: Reza R Serizawa, MD    +45 4488 4787 ext 82607    rerase01@herlevhosp.kbhamt.dk   
Principal Investigator: Reza R Serizawa, MD         
Sponsors and Collaborators
Copenhagen University Hospital at Herlev
Investigators
Principal Investigator: Reza R Serizawa, MD Copenhagen University Hospital at Herlev

ClinicalTrials.gov Identifier: NCT00244205     History of Changes
Other Study ID Numbers: Blæretumor PCR projekt
First Posted: October 26, 2005    Key Record Dates
Last Update Posted: November 15, 2005
Last Verified: November 2005

Additional relevant MeSH terms:
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases